Brilliant England

The England rugby team achieved a great victory against the All Blacks. I wish them every success for the final.




Withdrawal Treaty 2 versus just leaving

My long held view is I want to leave the EU as soon as possible without signing a Withdrawal Treaty. We should offer a free trade agreement to avoid the need for tariffs if the EU would agree to talks after we leave.

Opinion polling shows that just leaving is more popular than accepting Withdrawal Treaty 2. That commands just 19% support. It is more popular than Withdrawal Treaty 1. Withdrawal Treaty 2 is clearly an improvement on 1.  Polls also show a majority of those who want to just leave would rather sign Withdrawal Treaty 2 than remain or delay further if they cannot achieve their first preference thanks to this Remain oriented Parliament.

It is difficult to fathom why so few MPs make the public case for just leaving when it is a more popular option than the policies they advocate and when it is so obviously in the national interest. This dithering and delaying Parliament is creating continuing business uncertainty. It is talking us down. It is making us an international joke. Much of the governing establishment tells us by word or deed they think we should be governed by the EU and cannot manage to govern ourselves.

I thought Ministers, Shadow Ministers and MPs were employed to speak up for the UK, to create a realistic confidence in ourselves and our future. Instead many assist the EU in their negotiations, take their side in disputes when the government does speak up for us, and seem to take pleasure in any bad news as proof the public made the wrong decision.




Prosperity not austerity

On Thursday I set out the opportunity we have to set a new fiscal framework or economic policy once we are free of EU Treaty requirements. They have made us run our economy with the twin aims of cutting the government deficit and cutting state debt as a percentage of GDP. Labour, the Coalition and Conservatives in government since 2008 have accepted these imperatives and set the debt and deficit targets as required.

I recommend that the purpose of economic policy is changed to

The promotion of higher living standards through the growth in real incomes for all

The target should be

Government policy should aim to achieve over the next ten years a rise of one fifth in average individual spending power. Average net incomes should rise by one fifth plus the amount of inflation as measured by the CPI(H) index

The government should also continue to be prudent with public finances. It should adopt a Balanced budget rule. This should say

The government will ensure it collects enough revenue to pay for all current spending. It may apply a symmetric cyclical stabiliser, running a surplus during good growth and a deficit during a bad recession.

The government may borrow for public capital expenditure purposes. Each project approved must meet an appropriate test to establish it will make a decent economic return or to establish its importance to the provision of an approved list of public services free at the point of use.

This new fiscal framework would allow us to reduce the tax burden today to boost real incomes and promote more growth as a result




The costs of greening

Scottish Power have this week published a partial costing of how much the UK will need to spend in order to achieve the government’s stated target of zero net carbon dioxide from human sources by 2050.

Labour, the Lib Dems and Greens wish to accelerate this timetable. Glasgow plans to reach net zero as soon as 2030, and Liverpool by 2040, so these cities with a few others need to speed up their plans to convert current activities to hit their targets.

Councils and local bus companies can press on with replacing diesel and hybrid buses with electric vehicles. The state owned railway can carry on its expensive electrification schemes to switch more trains to all electric. The government can push the electricity industry harder to switch over to all renewables or carbon free generation. All of these come with a substantial public sector as well as private sector cost.

In two of the largest areas, cars and homes, individuals and families will need to meet most of the cost. The Scottish Power report tells us they think we will need 25 million electric charging points for electric cars to complete the transition. The Scottish government plans to phase out all diesel and petrol cars by 2032, with the UK government doing the same by 2040 where there is no quicker devolved government timetable. Their estimate of charger costs is £45bn, with additional costs to expand electricity output to meet the much enhanced demand. Individuals will have the investment costs of the vehicles to contend with.

The charger points will be partly financed by the private sector. I assume individuals will be responsible for the costs of chargers at home. Energy companies may put charger points into present filling stations or other suitable properties. Supermarkets and other companies and institutions may make public provision. Doubtless there will also be a taxpayer expense for various public sector charging points.

The Report says that 22 million homes will need to switch their current heating systems largely based on gas to electric powered heat pumps. This could cost £192 billion. Much of this cost will presumably fall on the consumer. I trust there would be financial help for those on low incomes as new boiler and heating systems with heat pumps are very expensive items if and when this becomes compulsory.

The UK has announced there will be no new gas boiler heating systems installed after 2025. There will be a substantial cost early in the next decade to retrain many heating engineers into the new technology.

I would be interested to hear your thoughts on all this, and in particular to know who wishes to be an early adopter of the new domestic heating systems recommended.




NHS England Concludes Wide-Ranging Deal For Cystic Fibrosis Drugs

This is excellent news which will be welcomed by my constituents who need to access effective cystic fibrosis medicines:

NHS England has today announced it has secured a definitive agreement with Vertex Pharmaceuticals to make available all three of their UK-licensed cystic fibrosis medicines. 

This means NHS patients will now have full access to Orkambi, Symkevi and Kalydeco, and around 5000 people may now take up these treatments. There is no cap on patient numbers, and each and every patient in England who might benefit can now get these treatments, free on the NHS. Clinicians will be able to begin prescribing these drugs within 30 days.

NHS England has been able to finalise this negotiation because the company agreed confidential commercial terms that constitute good value for British taxpayers and agreed to submit its drugs for full NICE appraisal.

The agreement provides access to all three drugs for all current licensed indications, as well as future licence extensions too. 

Investment in world-class, cutting edge technologies and treatments is at the heart of the NHS Long Term Plan. Over the last two years, as envisaged by the Accelerated Access Review, NHS England has established an expert commercial drugs team which has been working closely with industry and NICE, and has successfully negotiated a number of innovative deals, making new and promising treatments available for NHS patients. Recent such ‘smart deals’ include:

  • a deal to make ocrelizumab, an innovative multiple sclerosis drug available;
  • a ground-breaking deal which could eliminate Hepatitis C;
  • a £300 million saving after negotiating deals with five manufacturers on low cost versions of the health service’s most costly drug, adalimumab;
  • striking the first full access deal in Europe for CAR-T therapy via the Cancer Drugs Fund, which can potentially cure some children and adults with blood cancers where other treatments have failed, and;
  • reaching a deal to make the life-extending lung cancer drug pembrolizumab available for routine use on the NHS
  • a deal to make nusinersen available – the first treatment that targets the underlying cause of spinal muscular atrophy